Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392703 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT01392703 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 141 participants.
The verdict
NCT01392703, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.
Interventions
- DRUG Dasatinib as tablets
- DRUG Dasatinib as liquid
- DRUG Dasatinib as dispersed tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01392703
The ClinicalTrials.gov registry entry for NCT01392703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dasatinib as tablets is the first listed.
NCT01392703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01392703 about?
NCT01392703 is a clinical study titled "Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations". The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.
What is the current status of trial NCT01392703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2011-07. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01392703?
The interventions under investigation include: Dasatinib as tablets (DRUG), Dasatinib as liquid (DRUG), Dasatinib as dispersed tablets (DRUG).
Who is sponsoring clinical trial NCT01392703?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.